Pediatric acute myeloid leukemias treatment: current scientific view
The results of treatment of acute myeloid leukemias (AML) in children remain unsatisfactory. Modern therapeutic programs with hematopoietic stem cell transplantation allow us to get 5-year overall survival rate of 65 % in primary patients. For patients with relapses or refractory AML, 5-year overall...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/402 |
| _version_ | 1826557161016131584 |
|---|---|
| author | F. A. Makhacheva T. T. Valiev |
| author_facet | F. A. Makhacheva T. T. Valiev |
| author_sort | F. A. Makhacheva |
| collection | DOAJ |
| description | The results of treatment of acute myeloid leukemias (AML) in children remain unsatisfactory. Modern therapeutic programs with hematopoietic stem cell transplantation allow us to get 5-year overall survival rate of 65 % in primary patients. For patients with relapses or refractory AML, 5-year overall survival is about 35 %.This article presents the possibilities of chemotherapy and hematopoietic stem cell transplantation in the treatment of AML. The possibilities of epigenetic, immune, and cellular therapy are presented for pediatric AML. Special attention is paid to targeted drugs that only beginning to be used in the complex therapy of AML. |
| first_indexed | 2024-04-09T20:24:28Z |
| format | Article |
| id | doaj.art-915442413c4c454a90934e66476a8b8c |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2025-03-14T08:24:11Z |
| publishDate | 2020-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-915442413c4c454a90934e66476a8b8c2025-03-02T13:07:12ZrusABV-pressОнкогематология1818-83462413-40232020-04-01151102710.17650/1818-8346-2020-15-1-10-27336Pediatric acute myeloid leukemias treatment: current scientific viewF. A. Makhacheva0T. T. Valiev1N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaThe results of treatment of acute myeloid leukemias (AML) in children remain unsatisfactory. Modern therapeutic programs with hematopoietic stem cell transplantation allow us to get 5-year overall survival rate of 65 % in primary patients. For patients with relapses or refractory AML, 5-year overall survival is about 35 %.This article presents the possibilities of chemotherapy and hematopoietic stem cell transplantation in the treatment of AML. The possibilities of epigenetic, immune, and cellular therapy are presented for pediatric AML. Special attention is paid to targeted drugs that only beginning to be used in the complex therapy of AML.https://oncohematology.abvpress.ru/ongm/article/view/402acute myeloid leukemiatreatmentchildren |
| spellingShingle | F. A. Makhacheva T. T. Valiev Pediatric acute myeloid leukemias treatment: current scientific view Онкогематология acute myeloid leukemia treatment children |
| title | Pediatric acute myeloid leukemias treatment: current scientific view |
| title_full | Pediatric acute myeloid leukemias treatment: current scientific view |
| title_fullStr | Pediatric acute myeloid leukemias treatment: current scientific view |
| title_full_unstemmed | Pediatric acute myeloid leukemias treatment: current scientific view |
| title_short | Pediatric acute myeloid leukemias treatment: current scientific view |
| title_sort | pediatric acute myeloid leukemias treatment current scientific view |
| topic | acute myeloid leukemia treatment children |
| url | https://oncohematology.abvpress.ru/ongm/article/view/402 |
| work_keys_str_mv | AT famakhacheva pediatricacutemyeloidleukemiastreatmentcurrentscientificview AT ttvaliev pediatricacutemyeloidleukemiastreatmentcurrentscientificview |